| 000 | 01872 a2200577 4500 | ||
|---|---|---|---|
| 005 | 20250517071629.0 | ||
| 264 | 0 | _c20170717 | |
| 008 | 201707s 0 0 eng d | ||
| 022 | _a1527-3350 | ||
| 024 | 7 |
_a10.1002/hep.28422 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLawitz, Eric | |
| 245 | 0 | 0 |
_aSimeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). _h[electronic resource] |
| 260 |
_bHepatology (Baltimore, Md.) _c08 2016 |
||
| 300 |
_a360-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHepacivirus _xgenetics |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aSimeprevir _xtherapeutic use |
| 650 | 0 | 4 |
_aSofosbuvir _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aMatusow, Gary | |
| 700 | 1 | _aDeJesus, Edwin | |
| 700 | 1 | _aYoshida, Eric M | |
| 700 | 1 | _aFelizarta, Franco | |
| 700 | 1 | _aGhalib, Reem | |
| 700 | 1 | _aGodofsky, Eliot | |
| 700 | 1 | _aHerring, Robert W | |
| 700 | 1 | _aPoleynard, Gary | |
| 700 | 1 | _aSheikh, Aasim | |
| 700 | 1 | _aTobias, Hillel | |
| 700 | 1 | _aKugelmas, Marcelo | |
| 700 | 1 | _aKalmeijer, Ronald | |
| 700 | 1 | _aPeeters, Monika | |
| 700 | 1 | _aLenz, Oliver | |
| 700 | 1 | _aFevery, Bart | |
| 700 | 1 | _aDe La Rosa, Guy | |
| 700 | 1 | _aScott, Jane | |
| 700 | 1 | _aSinha, Rekha | |
| 700 | 1 | _aWitek, James | |
| 773 | 0 |
_tHepatology (Baltimore, Md.) _gvol. 64 _gno. 2 _gp. 360-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/hep.28422 _zAvailable from publisher's website |
| 999 |
_c25575648 _d25575648 |
||